Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
- Autores
- Garcia Fabiani, Maria Belen; Ventosa, Maria; Comba, Andrea; Candolfi, Marianela; Nicola Candia, Alejandro Javier; Alghamri, Mahmoud S.; Kadiyala, Padma; Carney, Stephen; Faisal, Syed M.; Schwendeman, Anna; Moon, James J.; Scheetz, Lindsay; Lahann, Joerg; Mauser, Ava; Lowenstein, Pedro R.; Castro, Maria Gabriela
- Año de publicación
- 2020
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy and surgical resection. Today, survival rates for malignant glioma patients remain dismal and unchanged for decades. The glioma microenvironment is highly immunosuppressive and consequently this has motivated the development of immunotherapies for counteracting this condition, enabling the immune cells within the tumor microenvironment to react against this tumor.Areas covered: The authors discuss immunotherapeutic strategies for glioma in phase-I/II clinical trials and illuminate their mechanisms of action, limitations and key challenges. They also examine promising approaches under preclinical development.Expert opinion: In the last decade there has been an expansion in immune-mediated anti-cancer therapies. In the glioma field, sophisticated strategies have been successfully implemented in preclinical models. Unfortunately, clinical trials have not yet yielded consistent results for glioma patients. This could be attributed to our limited understanding of the complex immune cell infiltration and its interaction with the tumor cells, the selected time for treatment, the combination with other therapies and the route of administration of the agent. Applying these modalities to treat malignant glioma is challenging, but many new alternatives are emerging to by-pass these hurdles.
Fil: Garcia Fabiani, Maria Belen. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ventosa, Maria. University of Michigan; Estados Unidos
Fil: Comba, Andrea. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Alghamri, Mahmoud S.. University of Michigan; Estados Unidos
Fil: Kadiyala, Padma. University of Michigan; Estados Unidos
Fil: Carney, Stephen. University of Michigan; Estados Unidos
Fil: Faisal, Syed M.. University of Michigan; Estados Unidos
Fil: Schwendeman, Anna. University of Michigan; Estados Unidos
Fil: Moon, James J.. University of Michigan; Estados Unidos
Fil: Scheetz, Lindsay. University of Michigan; Estados Unidos
Fil: Lahann, Joerg. University of Michigan; Estados Unidos
Fil: Mauser, Ava. University of Michigan; Estados Unidos
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
Fil: Castro, Maria Gabriela. University of Michigan; Estados Unidos - Materia
-
ANTIBODY
CAR T-CELL
CHECKPOINT INHIBITOR
DENDRITIC CELLS
GLIOMA
IMMUNOSUPPRESSION
IMMUNOTHERAPY
NANOPARTICLES
VACCINES
VIRUS - Nivel de accesibilidad
- acceso embargado
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/113423
Ver los metadatos del registro completo
id |
CONICETDig_ad2b294349b1862ac16eb4ac407226de |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/113423 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical developmentGarcia Fabiani, Maria BelenVentosa, MariaComba, AndreaCandolfi, MarianelaNicola Candia, Alejandro JavierAlghamri, Mahmoud S.Kadiyala, PadmaCarney, StephenFaisal, Syed M.Schwendeman, AnnaMoon, James J.Scheetz, LindsayLahann, JoergMauser, AvaLowenstein, Pedro R.Castro, Maria GabrielaANTIBODYCAR T-CELLCHECKPOINT INHIBITORDENDRITIC CELLSGLIOMAIMMUNOSUPPRESSIONIMMUNOTHERAPYNANOPARTICLESVACCINESVIRUShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy and surgical resection. Today, survival rates for malignant glioma patients remain dismal and unchanged for decades. The glioma microenvironment is highly immunosuppressive and consequently this has motivated the development of immunotherapies for counteracting this condition, enabling the immune cells within the tumor microenvironment to react against this tumor.Areas covered: The authors discuss immunotherapeutic strategies for glioma in phase-I/II clinical trials and illuminate their mechanisms of action, limitations and key challenges. They also examine promising approaches under preclinical development.Expert opinion: In the last decade there has been an expansion in immune-mediated anti-cancer therapies. In the glioma field, sophisticated strategies have been successfully implemented in preclinical models. Unfortunately, clinical trials have not yet yielded consistent results for glioma patients. This could be attributed to our limited understanding of the complex immune cell infiltration and its interaction with the tumor cells, the selected time for treatment, the combination with other therapies and the route of administration of the agent. Applying these modalities to treat malignant glioma is challenging, but many new alternatives are emerging to by-pass these hurdles.Fil: Garcia Fabiani, Maria Belen. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ventosa, Maria. University of Michigan; Estados UnidosFil: Comba, Andrea. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Alghamri, Mahmoud S.. University of Michigan; Estados UnidosFil: Kadiyala, Padma. University of Michigan; Estados UnidosFil: Carney, Stephen. University of Michigan; Estados UnidosFil: Faisal, Syed M.. University of Michigan; Estados UnidosFil: Schwendeman, Anna. University of Michigan; Estados UnidosFil: Moon, James J.. University of Michigan; Estados UnidosFil: Scheetz, Lindsay. University of Michigan; Estados UnidosFil: Lahann, Joerg. University of Michigan; Estados UnidosFil: Mauser, Ava. University of Michigan; Estados UnidosFil: Lowenstein, Pedro R.. University of Michigan; Estados UnidosFil: Castro, Maria Gabriela. University of Michigan; Estados UnidosTaylor & Francis2020-06info:eu-repo/date/embargoEnd/2021-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/113423Garcia Fabiani, Maria Belen; Ventosa, Maria; Comba, Andrea; Candolfi, Marianela; Nicola Candia, Alejandro Javier; et al.; Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development; Taylor & Francis; Expert Opinion on Investigational Drugs; 4; 6-2020; 1-261354-37841744-7658CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1768528info:eu-repo/semantics/altIdentifier/doi/10.1080/13543784.2020.1768528info:eu-repo/semantics/embargoedAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:09:53Zoai:ri.conicet.gov.ar:11336/113423instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:09:54.104CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development |
title |
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development |
spellingShingle |
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development Garcia Fabiani, Maria Belen ANTIBODY CAR T-CELL CHECKPOINT INHIBITOR DENDRITIC CELLS GLIOMA IMMUNOSUPPRESSION IMMUNOTHERAPY NANOPARTICLES VACCINES VIRUS |
title_short |
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development |
title_full |
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development |
title_fullStr |
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development |
title_full_unstemmed |
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development |
title_sort |
Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development |
dc.creator.none.fl_str_mv |
Garcia Fabiani, Maria Belen Ventosa, Maria Comba, Andrea Candolfi, Marianela Nicola Candia, Alejandro Javier Alghamri, Mahmoud S. Kadiyala, Padma Carney, Stephen Faisal, Syed M. Schwendeman, Anna Moon, James J. Scheetz, Lindsay Lahann, Joerg Mauser, Ava Lowenstein, Pedro R. Castro, Maria Gabriela |
author |
Garcia Fabiani, Maria Belen |
author_facet |
Garcia Fabiani, Maria Belen Ventosa, Maria Comba, Andrea Candolfi, Marianela Nicola Candia, Alejandro Javier Alghamri, Mahmoud S. Kadiyala, Padma Carney, Stephen Faisal, Syed M. Schwendeman, Anna Moon, James J. Scheetz, Lindsay Lahann, Joerg Mauser, Ava Lowenstein, Pedro R. Castro, Maria Gabriela |
author_role |
author |
author2 |
Ventosa, Maria Comba, Andrea Candolfi, Marianela Nicola Candia, Alejandro Javier Alghamri, Mahmoud S. Kadiyala, Padma Carney, Stephen Faisal, Syed M. Schwendeman, Anna Moon, James J. Scheetz, Lindsay Lahann, Joerg Mauser, Ava Lowenstein, Pedro R. Castro, Maria Gabriela |
author2_role |
author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
ANTIBODY CAR T-CELL CHECKPOINT INHIBITOR DENDRITIC CELLS GLIOMA IMMUNOSUPPRESSION IMMUNOTHERAPY NANOPARTICLES VACCINES VIRUS |
topic |
ANTIBODY CAR T-CELL CHECKPOINT INHIBITOR DENDRITIC CELLS GLIOMA IMMUNOSUPPRESSION IMMUNOTHERAPY NANOPARTICLES VACCINES VIRUS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy and surgical resection. Today, survival rates for malignant glioma patients remain dismal and unchanged for decades. The glioma microenvironment is highly immunosuppressive and consequently this has motivated the development of immunotherapies for counteracting this condition, enabling the immune cells within the tumor microenvironment to react against this tumor.Areas covered: The authors discuss immunotherapeutic strategies for glioma in phase-I/II clinical trials and illuminate their mechanisms of action, limitations and key challenges. They also examine promising approaches under preclinical development.Expert opinion: In the last decade there has been an expansion in immune-mediated anti-cancer therapies. In the glioma field, sophisticated strategies have been successfully implemented in preclinical models. Unfortunately, clinical trials have not yet yielded consistent results for glioma patients. This could be attributed to our limited understanding of the complex immune cell infiltration and its interaction with the tumor cells, the selected time for treatment, the combination with other therapies and the route of administration of the agent. Applying these modalities to treat malignant glioma is challenging, but many new alternatives are emerging to by-pass these hurdles. Fil: Garcia Fabiani, Maria Belen. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Ventosa, Maria. University of Michigan; Estados Unidos Fil: Comba, Andrea. University of Michigan; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina Fil: Nicola Candia, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina Fil: Alghamri, Mahmoud S.. University of Michigan; Estados Unidos Fil: Kadiyala, Padma. University of Michigan; Estados Unidos Fil: Carney, Stephen. University of Michigan; Estados Unidos Fil: Faisal, Syed M.. University of Michigan; Estados Unidos Fil: Schwendeman, Anna. University of Michigan; Estados Unidos Fil: Moon, James J.. University of Michigan; Estados Unidos Fil: Scheetz, Lindsay. University of Michigan; Estados Unidos Fil: Lahann, Joerg. University of Michigan; Estados Unidos Fil: Mauser, Ava. University of Michigan; Estados Unidos Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos Fil: Castro, Maria Gabriela. University of Michigan; Estados Unidos |
description |
Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy and surgical resection. Today, survival rates for malignant glioma patients remain dismal and unchanged for decades. The glioma microenvironment is highly immunosuppressive and consequently this has motivated the development of immunotherapies for counteracting this condition, enabling the immune cells within the tumor microenvironment to react against this tumor.Areas covered: The authors discuss immunotherapeutic strategies for glioma in phase-I/II clinical trials and illuminate their mechanisms of action, limitations and key challenges. They also examine promising approaches under preclinical development.Expert opinion: In the last decade there has been an expansion in immune-mediated anti-cancer therapies. In the glioma field, sophisticated strategies have been successfully implemented in preclinical models. Unfortunately, clinical trials have not yet yielded consistent results for glioma patients. This could be attributed to our limited understanding of the complex immune cell infiltration and its interaction with the tumor cells, the selected time for treatment, the combination with other therapies and the route of administration of the agent. Applying these modalities to treat malignant glioma is challenging, but many new alternatives are emerging to by-pass these hurdles. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-06 info:eu-repo/date/embargoEnd/2021-01-01 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/113423 Garcia Fabiani, Maria Belen; Ventosa, Maria; Comba, Andrea; Candolfi, Marianela; Nicola Candia, Alejandro Javier; et al.; Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development; Taylor & Francis; Expert Opinion on Investigational Drugs; 4; 6-2020; 1-26 1354-3784 1744-7658 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/113423 |
identifier_str_mv |
Garcia Fabiani, Maria Belen; Ventosa, Maria; Comba, Andrea; Candolfi, Marianela; Nicola Candia, Alejandro Javier; et al.; Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development; Taylor & Francis; Expert Opinion on Investigational Drugs; 4; 6-2020; 1-26 1354-3784 1744-7658 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1768528 info:eu-repo/semantics/altIdentifier/doi/10.1080/13543784.2020.1768528 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/embargoedAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
embargoedAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Taylor & Francis |
publisher.none.fl_str_mv |
Taylor & Francis |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1846083247068413952 |
score |
13.22299 |